- Report
- May 2024
- 129 Pages
Global
From €6160EUR$6,499USD£5,146GBP
- Report
- January 2022
- 200 Pages
Global
From €7109EUR$7,500USD£5,939GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1185EUR$1,250USD£990GBP
- Report
- January 2022
- 60 Pages
Global
From €3744EUR$3,950USD£3,128GBP
Candidemia is a type of fungal infection caused by the yeast Candida. It is a serious infection that can affect the bloodstream, heart, lungs, and other organs. Treatment for candidemia typically involves antifungal medications, such as fluconazole, voriconazole, and amphotericin B. These drugs are used to treat a variety of other fungal infections, as well as other infectious diseases.
The Candidemia Drug market is a subset of the larger Infectious Diseases Drugs market. It is composed of antifungal medications used to treat candidemia and other fungal infections. These drugs are used to treat a wide range of fungal infections, including those caused by Candida species, Aspergillus species, and Cryptococcus species.
The Candidemia Drug market is highly competitive, with many companies offering a variety of antifungal medications. Some of the major players in the market include Pfizer, Merck, GlaxoSmithKline, AstraZeneca, Novartis, Sanofi, and Johnson & Johnson. Show Less Read more